Page last updated: 2024-11-05

3-methoxybenzaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Methoxybenzaldehyde, also known as m-anisaldehyde, is an organic compound with the formula CH3OC6H4CHO. It is a colorless liquid with a sweet, aromatic odor. 3-Methoxybenzaldehyde is a versatile intermediate in organic synthesis and is used in the production of fragrances, pharmaceuticals, and other fine chemicals. It is also used as a flavoring agent in foods and beverages. The compound is synthesized via various methods, including the oxidation of 3-methoxytoluene or the formylation of anisole. Research into 3-methoxybenzaldehyde focuses on its potential applications in medicinal chemistry, particularly as a building block for the synthesis of bioactive compounds. Its pharmacological properties include antioxidant activity, anti-inflammatory effects, and potential anticancer activity. The compound has also been investigated for its use in the treatment of neurological disorders. 3-Methoxybenzaldehyde is an important molecule due to its diverse chemical and biological properties, making it a subject of ongoing research and development.'

3-methoxybenzaldehyde : A member of the class of benzaldehydes in which the hydrogen at position 3 of benzaldehyde has been replaced by a methoxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11569
CHEMBL ID22585
CHEBI ID136805
SCHEMBL ID23188
MeSH IDM0510257

Synonyms (68)

Synonym
8zao7s0ivh ,
4-08-00-00241 (beilstein handbook reference)
unii-8zao7s0ivh
brn 0606013
ccris 960
nsc 43794
einecs 209-712-8
ai3-52556
3-anisaldehyde
nsc-43794
metamethoxybenzaldehyde
nsc43794
m-anisaldehyde
m-methoxybenzaldehyde
inchi=1/c8h8o2/c1-10-8-4-2-3-7(5-8)6-9/h2-6h,1h
3-methoxybenzaldehyde
591-31-1
benzaldehyde, 3-methoxy-
m-anisaldehyde, >=97%
m-anisaldehyde, 97%
STK397887
meta-anisaldehyde
CHEBI:136805
meta-methoxybenzaldehyde
AC-2427
A0478
3-methoxy-benzaldehyde
CHEMBL22585
AKOS000119666
A832179
tox21_302136
dtxsid5044447 ,
dtxcid3024447
cas-591-31-1
NCGC00255778-01
FT-0615983
PS-3206
AB00318
SCHEMBL23188
3-methoxyphenylcarboxaldehyde
benzaldehyde, m-methoxy-
anisaldehyde, m-
5-methoxybenzaldehyde
m-anis-aldehyde
(3-methoxyphenyl)methanone
m-methoxy benzaldehyde
3-(methyloxy)benzaldehyde
3-methoxybenzaldhyde
3-methyoxybenzaldehyde
m-anisaldeyde
3-methoxy benzaldehyde
AM87084
STR00150
J-521677
CS-W007346
F2190-0576
mfcd00003361
m-anisaldehyde, purum, >=97.0% (gc)
m-anisaldehyde, analytical standard
m-anisaldehyde, 8ci
m-anisic aldehyde
SY001070
D70836
Q27271232
3-methoxybenzaldehde
HY-W007346
EN300-16136
Z53836050
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Brassica napus metaboliteAny plant metabolite that is produced by rapeseed (Brassica napus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
benzaldehydesAny arenecarbaldehyde that consists of a formyl substituted benzene ring and its substituted derivatives thereof.
monomethoxybenzeneCompounds containing a benzene skeleton substituted with one methoxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1291715Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative t2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291719Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID204561Concentration required to inhibit complement mediated hemolysis of sensitized sheep RBC2003Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7
Synthesis of low molecular weight compounds with complement inhibition activity.
AID1291714Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion by measuring minimal hemolytic dose preincubated with venom for 1 hr followed by administration to mo2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291717Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.28ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291718Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291721Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion by measuring minimal hemolytic dose administered immediately after venom injection measured after 24 hrs (Rvb =5 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291711Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID293934Inhibition of pieris rapae Phenoloxidase2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
3D-QSAR and molecular docking studies of benzaldehyde thiosemicarbazone, benzaldehyde, benzoic acid, and their derivatives as phenoloxidase inhibitors.
AID1544945Inhibition of NO711 binding to mouse GAT1 expressed in HEK293 cell membranes assessed as residual binding at 1 uM incubated for 4 hrs in presence of NO711 by LC-ESI-MS/MS analysis relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).
AID204263The concentration effective to cause 50% hemolysis with sensitized sheep erythrocytes in the absence of complement2003Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7
Synthesis of low molecular weight compounds with complement inhibition activity.
AID1291712Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291722Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291710Protective activity against Daboia russellii venom-induced mortality by measuring venom LD50 in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.28 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291716Lipophilicity, log P of compound2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291713Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (20.00)18.7374
1990's0 (0.00)18.2507
2000's4 (40.00)29.6817
2010's3 (30.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.67 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index69.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]